Impact of selected genetic factors on clopidogrel inactive metabolite level and antiplatelet response in patients after percutaneous coronary intervention.

ABSTRACT:

Background and objective

Clopidogrel is frequently used as part of optimal dual antiplatelet therapy in high-bleeding risk patients with the acute coronary syndrome. The concentration of the inactive carboxylic acid metabolite of clopidogrel might be useful to evaluate the response to clopidogrel therapy. Therefore, we sought to correlate the inhibition of platelet aggregation with the plasma level of the inactive metabolite of clopidogrel in patients after percutaneous coronary interventions (PCI) and their associations with the most frequently studied genetic polymorphisms. For this purpose, the fast and simple HPLC method for determining the concentration of the inactive metabolite was developed.

Methods

The effect of CYP2C19, CYP3A4/5, ABCB1 and PON1 genes on the plasma

SUBMITTER: Adamiak-Giera U 

PROVIDER: S-EPMC7994215 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature